

# Index

## B

- Bladder cancer, 101, 120, 121, 127–129, 133–134, 178
- Breast cancer, 21, 57, 61, 62, 86, 91–92, 101, 120, 121, 126–130, 165–167, 170, 177, 238

## C

- Capillary, 2, 3, 4, 11, 13, 16, 18, 21, 27, 33, 36, 46, 56, 122, 123, 160, 224, 232, 234–237, 239–241
- Cell trafficking, 162, 231, 237, 238
- Cervical cancer, 65, 92, 101, 121, 127–131
- Colorectal cancer, 61, 63, 70, 94, 95, 101, 121, 125, 127–129, 140, 141, 163

## D

- Days post fertilisation (Dfp), 35, 43, 47
- Development, 1, 2, 5, 6, 11–22, 27, 28, 31, 34, 36–39, 43, 45–47, 91, 122, 123, 125, 126, 132, 134, 137, 138, 159, 163–164, 168, 176, 177, 192, 194, 202, 203, 206, 217, 219, 222–224, 226, 227, 239, 242
- Dorsal aorta (DA), 16, 30, 32, 34, 37
- Dorsal caudal lymph vessel (DCLV), 29, 30, 42
- Dorsal longitudinal anastomosing vessel (DLAV), 29, 30

## E

- Enzyme-linked immunosorbent assay (ELISA), 61–63, 65–72, 125, 126
- Embryo, 2, 11, 15, 16, 18, 35, 42, 43, 224
- Endothelial cells, 2–7, 11, 13–16, 27, 29, 34–35, 38, 56, 73, 121–125, 129, 130, 135, 143, 144, 160, 162, 170, 191, 192, 195, 197–199, 202, 204, 205, 211, 217, 218, 223–226, 233–235, 237, 239, 241

- Esophageal cancer, 65, 88, 90, 95, 101, 120, 121, 128, 129, 139
- Estrogen, 93, 185, 191

## F

- Federation of Obstetrics and Gynecology (FIGO), 98, 130, 132
- Flow, 3, 4, 13, 14, 19, 20, 28, 159, 162, 163, 165, 172, 190, 231, 233–235, 237, 238, 241, 242

## G

- Gastric cancer, 57, 58, 61, 64, 69, 90, 99, 101–103, 120, 121, 127–129, 141, 142
- Green fluorescent protein (GFP), 35–37, 44, 46, 48
- Growth factor receptors, 1, 2, 56, 96, 160
- Growth factors, 1, 3, 5, 56, 57, 60, 61, 70–74, 121, 125, 132, 137, 144, 159, 160, 162, 163, 179, 185, 199, 201, 203, 212, 223, 238, 239, 241

## H

- Head and neck cancer, 59, 87, 90, 96, 121, 127–129, 136
- Head and neck squamous cell carcinoma (HNSCC), 136–138
- Hematoxylin and eosin (H&E), 90, 121
- Hepatocellular cancer, 96, 121, 127–129, 143

## I

- Imaging, 5, 48, 55, 83–88, 159–180, 187
- Interstitium, 197, 232–233, 235, 236

## K

- Kaposi's sarcoma, 4, 211–227
- Kaposi's sarcoma herpesvirus (KSHV), 211–227

**L**

- LAM cell cluster (LCC), 185, 191, 196, 197–199, 202–205
- LAM cells, 185, 186, 190–200, 202–206
- Lung cancer, 57, 66, 87, 90, 120, 121, 127–129, 143
- Lymphangioliomyomatosis (LAM), 4, 185–206
- Lymph heart (LH), 14, 28, 29
- Lymph node dissection, 83, 103, 105, 134, 138, 167, 168
- Lymph node imaging, 83, 170, 171, 176
- Lymph node staging, 83
- Lymph node, 2–5, 11, 12, 21, 34, 55–74, 83–106, 119, 120, 124–127, 129–146, 159–180, 185, 186, 188, 189, 191, 192, 194, 195, 197, 199, 200, 202, 203, 205, 206, 211, 219, 222, 225, 226, 231–234, 237–242
- Lymph nodes metastases, 2, 5, 55–74, 83–106, 119, 120, 125, 127, 130–145, 167, 202, 205, 206, 240
- Lymphangiogenesis, 1–7, 11, 15, 21, 27–49, 55–61, 69–74, 119–146, 159–180, 185, 195–197, 199–206, 223, 225, 226, 239–242
- Lymphangiogenic growth factor, 1, 3, 57, 60, 61, 70–74, 119, 121, 125, 137, 185, 199, 201, 203, 239
- Lymphangion, 231, 233, 235, 237
- Lymphatic metastasis, 3, 5, 55, 57, 69, 89, 119, 135, 138, 160, 162, 201, 231, 239, 240, 242
- See also* Metastasis
- Lymphatic vessel density, 57–59, 68, 69, 119–124, 127–143, 145, 239, 240, 242
- Lymphatic vessel endothelial HA receptor (LYVE), 6, 16, 58, 121–123, 129, 131, 132, 136, 137, 143, 145, 162, 195, 223, 224, 236

**M**

- Melanoma, 43, 57–59, 61, 62, 69, 83, 86, 89–91, 97, 98, 100, 103–105, 120, 121, 127–129, 135, 136, 161, 165, 166, 168, 169, 178, 191, 198, 241
- Metastasis, 1–3, 5, 6, 11, 27, 55–74, 83–106, 119–121, 123, 125–128, 130–145, 159–164, 167, 168, 170, 173, 174, 176, 195, 199, 201–206, 219, 230, 238–242
- Mouse, 2, 5, 11, 15, 16, 18, 19, 21, 27, 28, 31–33, 37–39, 45, 48, 49, 57–59, 61, 67, 73, 126, 175–177, 179, 201, 206, 226, 237

**N**

- N*-ethyl-*N*-nitrosourea (ENU), 39, 40, 44, 45
- Nuclear localisation signal (NLS), 37

**O**

- Ovarian cancer, 67, 98, 99, 121, 127–129, 131, 132

**P**

- Pancreatic cancer, 99, 101, 103, 121, 142
- Parachordal vessel (PAV), 37, 49
- Posterior cardinal vein (PCV), 29, 30, 35, 49
- Prognosis, 4, 59, 61–69, 83, 92, 105, 119, 120, 125, 127, 130, 132, 134, 136–145, 160–162, 168, 179, 241
- Prostate cancer, 57, 58, 67, 88, 99, 120, 121, 127–129, 132, 133, 164, 172, 174
- Prostate specific antigen (PSA), 99, 132, 133
- Prox1, 11, 16, 18, 19, 21, 28–32, 35, 37, 41, 58, 223, 224, 236

**R**

- Renal cell cancer, 121, 127–129, 134
- Reverse transcriptase polymerase chain reaction (RT-PCR), 61–68, 70, 71, 90, 91, 125
- Rostral lymph sac (RLS), 28, 29

**S**

- Sentinel lymph node (SLN), 3, 4, 55, 57, 59–61, 69, 120, 136, 161, 165–167, 168–170, 176–178, 180
- Spindle cells, 211, 216–219, 223–226

**T**

- Targeting induced local lesions in genomes (TILLING), 39, 40, 41, 45, 48
- Thyroid cancer, 68, 83, 87, 100, 121, 127–129, 138
- Transgenic (Tg), 32–34, 42–44, 46–48, 57, 59, 202
- Tuberous sclerosis complex (TSC), 185, 186, 188, 192, 194, 195, 199, 201, 205

**V**

- Vascular endothelial growth factor (VEGF), 2, 3, 6, 55, 56, 121, 160, 224, 238, 241
- Vascular endothelial growth factor A (VEGF-A), 55–57, 59, 60, 62–69, 71–73, 125, 130, 137, 144, 163, 179, 200, 201

- Vascular endothelial growth factor C  
(VEGF-C), 2–6, 16, 18, 31, 34,  
38, 41, 46, 49, 55–74, 121, 123,  
125, 127, 128, 130–132, 134–145,  
160, 162, 163, 179, 185, 199–203,  
205, 206, 223, 224, 226, 231,  
238–242
- Vascular endothelial growth factor D  
(VEGF-D), 2–6, 55–58, 61–73,  
121, 123, 125, 127, 128, 131–135,  
138–145, 160, 162, 163, 179, 185,  
199–203, 223
- Vascular endothelial growth factor receptor 3  
(VEGFR3), 2
- Vasculature, 1, 2, 4, 6, 11–22, 27–30, 34–37,  
42, 43, 47, 124, 161, 202, 205, 236
- Ventral caudal lymph vessel (VCLV),  
28–30, 34
- X**
- Xenopus*, 27, 31–33, 38–42, 49
- Z**
- Zebrafish, 6, 15, 27, 28, 31–40, 43–49